These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. The design, synthesis and biological evaluation of 7-alkoxy-4-heteroarylamino-3-cyanoquinolines as dual inhibitors of c-Src and iNOS. Cao X; You QD; Li ZY; Liu XR; Xu D; Guo QL; Shang J; Chern JW; Chen ML Bioorg Med Chem Lett; 2008 Dec; 18(23):6206-9. PubMed ID: 18930653 [TBL] [Abstract][Full Text] [Related]
9. Inhibition of Tpl2 kinase and TNF-alpha production with 1,7-naphthyridine-3-carbonitriles: synthesis and structure-activity relationships. Gavrin LK; Green N; Hu Y; Janz K; Kaila N; Li HQ; Tam SY; Thomason JR; Gopalsamy A; Ciszewski G; Cuozzo JW; Hall JP; Hsu S; Telliez JB; Lin LL Bioorg Med Chem Lett; 2005 Dec; 15(23):5288-92. PubMed ID: 16165349 [TBL] [Abstract][Full Text] [Related]
10. Synthesis and Src kinase inhibitory activity of 2-phenyl- and 2-thienyl-7-phenylaminothieno[3,2-b]pyridine-6-carbonitriles. Boschelli DH; Wu B; Barrios Sosa AC; Durutlic H; Chen JJ; Wang Y; Golas JM; Lucas J; Boschelli F J Med Chem; 2005 Jun; 48(11):3891-902. PubMed ID: 15916442 [TBL] [Abstract][Full Text] [Related]
11. Facile preparation of new 4-phenylamino-3-quinolinecarbonitrile Src kinase inhibitors via 7-fluoro intermediates: identification of potent 7-amino analogs. Boschelli DH; Wu B; Ye F; Durutlic H; Golas JM; Lucas J; Boschelli F Bioorg Med Chem; 2008 Jan; 16(1):405-12. PubMed ID: 17905586 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of Tpl2 kinase and TNFalpha production with quinoline-3-carbonitriles for the treatment of rheumatoid arthritis. Hu Y; Green N; Gavrin LK; Janz K; Kaila N; Li HQ; Thomason JR; Cuozzo JW; Hall JP; Hsu S; Nickerson-Nutter C; Telliez JB; Lin LL; Tam S Bioorg Med Chem Lett; 2006 Dec; 16(23):6067-72. PubMed ID: 16973359 [TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo evaluation of 6-aminopyrazolyl-pyridine-3-carbonitriles as JAK2 kinase inhibitors. Wang T; Ioannidis S; Almeida L; Block MH; Davies AM; Lamb ML; Scott DA; Su M; Zhang HJ; Alimzhanov M; Bebernitz G; Bell K; Zinda M Bioorg Med Chem Lett; 2011 May; 21(10):2958-61. PubMed ID: 21493067 [TBL] [Abstract][Full Text] [Related]
14. SKI-606, a Src/Abl inhibitor with in vivo activity in colon tumor xenograft models. Golas JM; Lucas J; Etienne C; Golas J; Discafani C; Sridharan L; Boghaert E; Arndt K; Ye F; Boschelli DH; Li F; Titsch C; Huselton C; Chaudhary I; Boschelli F Cancer Res; 2005 Jun; 65(12):5358-64. PubMed ID: 15958584 [TBL] [Abstract][Full Text] [Related]
15. Synthesis and biological evaluation of sulfonylhydrazone-substituted imidazo[1,2-a]pyridines as novel PI3 kinase p110alpha inhibitors. Hayakawa M; Kawaguchi K; Kaizawa H; Koizumi T; Ohishi T; Yamano M; Okada M; Ohta M; Tsukamoto S; Raynaud FI; Parker P; Workman P; Waterfield MD Bioorg Med Chem; 2007 Sep; 15(17):5837-44. PubMed ID: 17601739 [TBL] [Abstract][Full Text] [Related]
16. Design and synthesis of orally bioavailable benzimidazoles as Raf kinase inhibitors. Ramurthy S; Subramanian S; Aikawa M; Amiri P; Costales A; Dove J; Fong S; Jansen JM; Levine B; Ma S; McBride CM; Michaelian J; Pick T; Poon DJ; Girish S; Shafer CM; Stuart D; Sung L; Renhowe PA J Med Chem; 2008 Nov; 51(22):7049-52. PubMed ID: 18942827 [TBL] [Abstract][Full Text] [Related]
17. RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer. Iverson C; Larson G; Lai C; Yeh LT; Dadson C; Weingarten P; Appleby T; Vo T; Maderna A; Vernier JM; Hamatake R; Miner JN; Quart B Cancer Res; 2009 Sep; 69(17):6839-47. PubMed ID: 19706763 [TBL] [Abstract][Full Text] [Related]
18. Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: design, synthesis, and evaluation. Harmange JC; Weiss MM; Germain J; Polverino AJ; Borg G; Bready J; Chen D; Choquette D; Coxon A; DeMelfi T; DiPietro L; Doerr N; Estrada J; Flynn J; Graceffa RF; Harriman SP; Kaufman S; La DS; Long A; Martin MW; Neervannan S; Patel VF; Potashman M; Regal K; Roveto PM; Schrag ML; Starnes C; Tasker A; Teffera Y; Wang L; White RD; Whittington DA; Zanon R J Med Chem; 2008 Mar; 51(6):1649-67. PubMed ID: 18324761 [TBL] [Abstract][Full Text] [Related]
19. Potent and selective mitogen-activated protein kinase kinase (MEK) 1,2 inhibitors. 1. 4-(4-bromo-2-fluorophenylamino)-1- methylpyridin-2(1H)-ones. Wallace EM; Lyssikatos J; Blake JF; Seo J; Yang HW; Yeh TC; Perrier M; Jarski H; Marsh V; Poch G; Livingston MG; Otten J; Hingorani G; Woessner R; Lee P; Winkler J; Koch K J Med Chem; 2006 Jan; 49(2):441-4. PubMed ID: 16420026 [TBL] [Abstract][Full Text] [Related]